GB202202711D0 - ProC3 and TGFBI in cancer - Google Patents

ProC3 and TGFBI in cancer

Info

Publication number
GB202202711D0
GB202202711D0 GBGB2202711.4A GB202202711A GB202202711D0 GB 202202711 D0 GB202202711 D0 GB 202202711D0 GB 202202711 A GB202202711 A GB 202202711A GB 202202711 D0 GB202202711 D0 GB 202202711D0
Authority
GB
United Kingdom
Prior art keywords
proc3
tgfbi
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2202711.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyBioscience AG
Original Assignee
KeyBioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG filed Critical KeyBioscience AG
Priority to GBGB2202711.4A priority Critical patent/GB202202711D0/en
Publication of GB202202711D0 publication Critical patent/GB202202711D0/en
Ceased legal-status Critical Current

Links

GBGB2202711.4A 2022-02-28 2022-02-28 ProC3 and TGFBI in cancer Ceased GB202202711D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2202711.4A GB202202711D0 (en) 2022-02-28 2022-02-28 ProC3 and TGFBI in cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2202711.4A GB202202711D0 (en) 2022-02-28 2022-02-28 ProC3 and TGFBI in cancer

Publications (1)

Publication Number Publication Date
GB202202711D0 true GB202202711D0 (en) 2022-04-13

Family

ID=81075615

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2202711.4A Ceased GB202202711D0 (en) 2022-02-28 2022-02-28 ProC3 and TGFBI in cancer

Country Status (1)

Country Link
GB (1) GB202202711D0 (en)

Similar Documents

Publication Publication Date Title
IL288485A (en) Anti-trop2 antibody-drug conjugates for use in treating cancer
ZA202100195B (en) Purinone compounds and their use in treating cancer
EP3883610A4 (en) Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
EP3906096A4 (en) Methods and compositions for treating cancer with immune cells
EP4066837A4 (en) Use of bi853520 in cancer treatment
PT3790879T (en) Triazolopyrimidine compounds and their use in treating cancer
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
IL276768A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
IL280617A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
IL292143A (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
EP3969121A4 (en) Methods and compositions for treating non-small cell lung cancer
EP3703757A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4110822A4 (en) Compositions and methods for treating cancer
EP4127722A4 (en) Methods and compositions for treating cancer
GB202302820D0 (en) ProC3 and TGFBI in cancer
GB202202711D0 (en) ProC3 and TGFBI in cancer
EP4038222A4 (en) Methods and compositions for identifying neoantigens for use in treating and preventing cancer
IL308058A (en) Molephantin derivatives useful in the treatment of cancer
IL308992A (en) Treatment of cancer in patients with soluble fr-alpha
IL306090A (en) Targeted therapies in cancer
IL289596A (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB202101728D0 (en) Compounds and their use treating cancer
EP4103738A4 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
EP3946313A4 (en) Plk1 inhibitors and psa levels in prostate cancer
EP3891123A4 (en) Oligo-benzamide analogs and their use in cancer treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)